Patent · US Active

Therapeutic methods that target the NCCA-ATP channel

US10583094B2 · kind B2 · utility

0Cited by
38References
54Claims
0Family size

Assignees

Inventors

Key dates

Filing dateJul 25, 2005
Grant dateMar 10, 2020
Priority date
Expiry dateFeb 19, 2031

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K14/4705
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention is directed to therapeutic compositions targeting the NCCa-ATP channel of an astrocyte, neuron or capillary endothelial cell and methods of using same. More specifically, agonists and antagonists of the NCCa-ATP channel are contemplated. The therapeutic compositions are used to treat cancer, more specifically, a metastatic brain tumor, wherein a tumor-brain barrier is present. Such treatments are contemplated in combination with conventional anti-cancer therapies. Alternatively, the compositions are used to prevent cell death and to treat cerebral edema that result from ischemia, due to interruption of blood flow, to tissue trauma or to increased tissue pressure.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.